ISSN 1673-5765 CN 11-5434/R
Chinese Journal of Stroke ›› 2024, Vol. 19 ›› Issue (7): 747-754.DOI: 10.3969/j.issn.1673-5765.2024.07.003
Previous Articles Next Articles
Moyamoya Angiopathy and Immune-Related Diseases
WANG Minjie1,2, HAN Cong1,2, DUAN Lian1,2
1 Department of Neurosurgery, The First Medical Center of Chinese PLA General Hospital, Beijing 100039, China
2 Department of Neurosurgery, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China
Received:2024-04-30
Online:2024-07-20
Published:2024-07-20
Contact:
DUAN Lian, E-mail: duanlian307@sina.com
烟雾血管病与免疫相关疾病
汪敏杰1，2，韩聪1，2，段炼1，2
1 北京 100039 中国人民解放军总医院第一医学中心神经外科医学部
2 中国人民解放军总医院第五医学中心神经外科
通讯作者:
段炼 duanlian307@sina.com
CLC Number:
WANG Minjie, HAN Cong, DUAN Lian.
Moyamoya Angiopathy and Immune-Related Diseases [J]. Chinese Journal of Stroke, 2024, 19(7): 747-754.
汪敏杰, 韩聪, 段炼.
烟雾血管病与免疫相关疾病 [J]. 中国卒中杂志, 2024, 19(7): 747-754.
| [1] SCOTT R M，SMITH E R. Moyamoya disease and Moyamoya syndrome[J]. N Engl J Med，2009，360（12）：1226-1237. [2] SUZUKI J，TAKAKU A. Cerebrovascular “Moyamoya” disease. Disease showing abnormal net-like vessels in base of brain[J]. Arch Neurol，1969，20（3）：288-299. [3] MUGIKURA S，TAKAHASHI S. Posterior circulation in Moyamoya[J]. J Neurosurg，2014，120（5）：1240-1241. [4] BERSANO A，KHAN N，FUENTES B，et al. European Stroke Organisation（ESO）guidelines on Moyamoya angiopathy endorsed by vascular european reference network（VASCERN）[J]. Eur Stroke J，2023，8（1）：55-84. [5] LIU X M，RUAN X Z，CAI Z，et al. Moyamoya disease caused by leptospiral cerebral arteritis[J]. Chin Med J（Engl），1980，93（9）：599-604. [6] BURKE G M，BURKE A M，SHERMA A K，et al. Moyamoya disease：a summary[J/OL]. Neurosurg Focus，2009，26（4）：E11[2024-03-22]. http://doi.org/10.3171/2009.1.FOCUS08310. [7] TANIGAWARA T，YAMADA H，SAKAI N，et al. Studies on cytomegalovirus and Epstein-Barr virus infection in Moyamoya disease[J/OL]. Clin Neurol Neurosurg，1997，99 Suppl 2：S225-S228[2024-03-22]. http://doi.org/10.1016/s0303-8467（97）00049-8. [8] PALACIO S，HART R G，VOLLMER D G，et al. Late-developing cerebral arteropathy after pyogenic meningitis[J]. Arch Neurol，2003，60（3）：431-433. [9] CZARTOSKI T，HALLAM D，LACY J M，et al. Postinfectious vasculopathy with evolution to Moyamoya syndrome[J]. J Neurol Neurosurg Psychiatry，2005，76（2）：256-259. [10] KHAN F Y，KAMAL H，MUSA R，et al. Moyamoya syndrome in a known case of pulmonary tuberculosis[J]. J Neurosci Rural Pract，2010，1（2）：105-108. [11] GHOSH R，DUBEY S，KANTI RAY B，et al. COVID-19 presenting with thalamic hemorrhage unmasking Moyamoya angiopathy[J]. Can J Neurol Sci，2020，47（6）：849-851. [12] EZURA M，FUJIWARA S，NOSE M，et al. Attempts to induce immune-mediated cerebral arterial injury for an experimental model of Moyamoya disease[J]. Childs Nerv Syst，1992，8（5）：263-267. [13] 张海鸥，饶明俐，张淑琴，等. 烟雾病病因和发病机理的实验研究[J]. 中华神经科杂志，1996，29（3）：51-54，66. ZHANG H O，RAO M L，ZHANG S Q，et al. An experimental study on the etiology and pathogenesis of Moyamoya disease[J]. Chin J Neurol，1996，29（3）：51-54，66. [14] ELEFTHERIOU D，DILLON M J，BROGAN P A. Advances in childhood vasculitis[J]. Curr Opin Rheumatol，2009，21（4）：411-418. [15] LUO Y T，CAO Z X，WU S Q，et al. Ring finger protein 213 in Moyamoya disease with pulmonary arterial hypertension：a mini-review[J/OL]. Front Neurol，2022，13：843927[2024-03-22]. http://doi.org/10.3389/fneur.2022.843927. [16] VAN DER VLIET J A，ZEILSTRA D J，VAN ROYE S F，et al. Renal artery stenosis in Moyamoya syndrome[J]. J Cardiovasc Surg（Torino），1994，35（5）：441-443. [17] KAWASAKI T，ARAKAWA Y，SUGINO T，et al. Three cases of Moyamoya disease with a history of Kawasaki disease[J]. No Shinkei Geka，2015，43（11）：1005-1010. [18] CHEN J B，LIU Y，ZHOU L X，et al. Prevalence of autoimmune disease in Moyamoya disease patients in Western Chinese population[J]. J Neurol Sci，2015，351（1/2）：184-186. [19] CHEN J B，LIU Y，ZHOU L X，et al. Increased prevalence of autoimmune disease in patients with unilateral compared with bilateral Moyamoya disease[J]. J Neurosurg，2016，124（5）：1215-1220. [20] BOWER R S，MALLORY G W，NWOJO M，et al. Moyamoya disease in a primarily white，Midwestern US population：increased prevalence of autoimmune disease[J]. Stroke，2013，44（7）：1997-1999. [21] LI D S，YANG W Z，XIAN P，et al. Coexistence of Moyamoya and Graves’ diseases：the clinical characteristics and treatment effects of 21 Chinese patients[J]. Clin Neurol Neurosurg，2013，115（9）：1647-1652. [22] NI J，ZHOU L X，WEI Y P，et al. Moyamoya syndrome associated with Graves’ disease：a case series study[J/OL]. Ann Transl Med，2014，2（8）：77[2024-03-22]. http://doi.org/10.3978/j.issn.2305-5839.2014.08.03. [23] OHBA S，NAKAGAWA T，MURAKAMI H. Concurrent Graves’ disease and intracranial arterial stenosis/occlusion：special considerations regarding the state of thyroid function，etiology，and treatment[J]. Neurosurg Rev，2011，34（3）：297-304. [24] PACIARONI M，MICHELI S，CASO V，et al. Angiographic findings of Moyamoya vessels in a patient with rheumatoid arthritis[J]. Cerebrovasc Dis，2005，20（5）：415-416. [25] TRUEDSSON L，BENGTSSON A A，STURFELT G. Complement deficiencies and systemic lupus erythematosus[J]. Autoimmunity，2007，40（8）：560-566. [26] MATSUKI Y，KAWAKAMI M，ISHIZUKA T，et al. SLE and Sjögren’s syndrome associated with unilateral Moyamoya vessels in cerebral arteries[J]. Scand J Rheumatol，1997，26（5）：392-394. [27] YAMASHITA Y，KUSAGA A，KOGA Y，et al. Noonan syndrome，Moyamoya-like vascular changes，and antiphospholipid syndrome[J]. Pediatr Neurol，2004，31（5）：364-366. [28] CHO S M，DI LORENZO R，MYLES J L，et al. Severe hyperhomocysteinemia manifesting as Moyamoya vasculopathy and Henoch-Schonlein purpura[J]. Neurology，2018，91（7）：321-323. [29] DEGIRMENCI E，BIR L S，YAGCı B，et al. Moyamoya syndrome or Behçet’s disease？[J]. Int J Rheum Dis，2014，17（8）：920-922. [30] PREZIOSA P，MARTINELLI V，FERRè L，et al. Moyamoya disease mimicking the first attack of multiple sclerosis[J]. J Neurol，2017，264（5）：1005-1007. [31] UTKU U，ASIL T，CELIK Y，et al. Reversible MR angiographic findings in a patient with autoimmune Graves disease[J]. AJNR Am J Neuroradiol，2004，25（9）：1541-1543. [32] DUAN L，WEI L，TIAN Y H，et al. Novel susceptibility loci for Moyamoya disease revealed by a genome-wide association study[J]. Stroke，2018，49（1）：11-18. [33] LIU W Y，MORITO D，TAKASHIMA S，et al. Identification of RNF213 as a susceptibility gene for Moyamoya disease and its possible role in vascular development[J/OL]. PLoS One，2011，6（7）：e22542[2024-03-22]. http://doi.org/10.1371/journal.pone.0022542. [34] KAMADA F，AOKI Y，NARISAWA A，et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene[J]. J Hum Genet，2011，56（1）：34-40. [35] ASSELMAN C，HEMELSOET D，EGGERMONT D，et al. Moyamoya disease emerging as an immune-related angiopathy[J]. Trends Mol Med，2022，28（11）：939-950. [36] SHOEMAKER L D，CLARK M J，PATWARDHAN A，et al. Disease variant landscape of a large multiethnic population of Moyamoya patients by exome sequencing[J]. G3（Bethesda），2015，6（1）：41-49. [37] LIU W Y，HITOMI T，KOBAYASHI H，et al. Distribution of Moyamoya disease susceptibility polymorphism p.R4810K in RNF213 in East and Southeast Asian populations[J]. Neurol Med Chir（Tokyo），2012，52（5）：299-303. [38] CECCHI A C，GUO D C，REN Z，et al. RNF213 rare variants in an ethnically diverse population with Moyamoya disease[J]. Stroke，2014，45（11）：3200-3207. [39] HOUZELSTEIN D，SIMON-CHAZOTTES D，BATISTA L，et al. The ring finger protein 213 gene（RNF213）contributes to rift valley fever resistance in mice[J]. Mamm Genome，2021，32（1）：30-37. [40] NOAD J，VON DER MALSBURG A，PATHE C，et al. LUBAC-synthesized linear ubiquitin chains restrict cytosol-invading bacteria by activating autophagy and NF-κB[J/OL]. Nat Microbiol，2017，2：17063[2024-03-22]. http://doi.org/10.1038/nmicrobiol.2017.63. [41] VAN WIJK S J L，FRICKE F，HERHAUS L，et al. Linear ubiquitination of cytosolic salmonella typhimurium activates NF-κB and restricts bacterial proliferation[J/OL]. Nat Microbiol，2017，2：17066[2024-03-22]. http://doi.org/10.1038/nmicrobiol.2017.66. [42] OTTEN E G，WERNER E，CRESPILLO-CASADO A，et al. Ubiquitylation of lipopolysaccharide by RNF213 during bacterial infection[J]. Nature，2021，594（7861）：111-116. [43] THERY F，MARTINA L，ASSELMAN C，et al. Ring finger protein 213 assembles into a sensor for ISGylated proteins with antimicrobial activity[J/OL]. Nat Commun，2021，12（1）：5772[2024-03-22]. http://doi.org/10.1038/s41467-021-26061-w. [44] TASHIRO R，NIIZUMA K，KASAMATSU J，et al. Dysregulation of RNF213 gene contributes to T cell response via antigen uptake，processing，and presentation[J]. J Cell Physiol，2021，236（11）：7554-7564. [45] KITAHARA T，OKUMURA K，SEMBA A，et al. Genetic and immunologic analysis on Moyamoya[J]. J Neurol Neurosurg Psychiatry，1982，45（11）：1048-1052. [46] AOYAGI M，OGAMI K，MATSUSHIMA Y，et al. Human leukocyte antigen in patients with Moyamoya disease[J]. Stroke，1995，26（3）：415-417. [47] INOUE T K，IKEZAKI K，SASAZUKI T，et al. DNA typing of HLA in the patients with Moyamoya disease[J]. Jpn J Hum Genet，1997，42（4）：507-515. [48] WAN J，LING W，ZHENGSHAN Z，et al. Association of HLA-DQA2 and HLA-B with Moyamoya disease in the Chinese Han population[J/OL]. Neurol Genet，2021，7（3）：e592[2024-03-22]. http://doi.org/10.1212/NXG.0000000000000592. [49] KRAEMER M，HORN P A，RODER C，et al. Analysis of human leucocyte antigen genes in Caucasian patients with idiopathic Moyamoya angiopathy[J]. Acta Neurochir（Wien），2012，154（3）：445-454. [50] HONG S H，WANG K C，KIM S K，et al. Association of HLA-DR and -DQ genes with familial Moyamoya disease in Koreans[J]. J Korean Neurosurg Soc，2009，46（6）：558-563. [51] TASHIRO R，NIIZUMA K，KHOR S S，et al. Identification of HLA-DRB1*04：10 allele as risk allele for Japanese Moyamoya disease and its association with autoimmune thyroid disease：a case-control study[J/OL]. PLoS One，2019，14（8）：e0220858[2024-03-22]. http://doi.org/10.1371/journal.pone.0220858. [52] SALAZAR M，VARELA A，RAMIREZ L A，et al. Association of HLA-DRB1*1602 and DRB1*1001 with Takayasu arteritis in Colombian mestizos as markers of Amerindian ancestry[J/OL]. Int J Cardiol，2000，75 Suppl 1：S113-S116[2024-03-22]. http://doi.org/10.1016/s0167-5273（00）00181-9. [53] HIROHATA S，INOUE T，ITO K. Development of rheumatoid arthritis after chronic hepatitis caused by hepatitis C virus infection[J]. Intern Med，1992，31（4）：493-495. [54] ROY V，ROSS J P，PéPIN R，et al. Moyamoya disease susceptibility gene RNF213 regulates endothelial barrier function[J]. Stroke，2022，53（4）：1263-1275. [55] LOUVRIER C，AWAD F，COSNES A，et al. RNF213-associated urticarial lesions with hypercytokinemia[J]. J Allergy Clin Immunol，2022，150（6）：1545-1555. [56] SHEN W J，LIAO Y J，GARCIA R，et al. Association of CD40 SNPs with Moyamoya in a Chinese children population[J]. Br J Neurosurg，2019，33（4）：398-401. [57] ITO A，FUJIMURA M，NIIZUMA K，et al. Enhanced post-ischemic angiogenesis in mice lacking RNF213; a susceptibility gene for Moyamoya disease[J/OL]. Brain Res，2015，1594：310-320[2024-03-22]. http://doi.org/10.1016/j.brainres.2014.11.014. [58] SUGIHARA M，MORITO D，AINUKI S，et al. The AAA+ ATPase/ubiquitin ligase mysterin stabilizes cytoplasmic lipid droplets[J]. J Cell Biol，2019，218（3）：949-960. [59] TAKEDA M，TEZUKA T，KIM M，et al. Moyamoya disease patient mutations in the RING domain of RNF213 reduce its ubiquitin ligase activity and enhance NFκB activation and apoptosis in an AAA+ domain-dependent manner[J]. Biochem Biophys Res Commun，2020，525（3）：668-674. [60] YE F，NIU X Y，LIANG F，et al. RNF213 loss-of-function promotes pathological angiogenesis in Moyamoya disease via the hippo pathway[J]. Brain，2023，146（11）：4674-4689. [61] ZHANG L Y，RASHAD S，ZHOU Y，et al. RNF213 loss of function reshapes vascular transcriptome and spliceosome leading to disrupted angiogenesis and aggravated vascular inflammatory responses[J]. J Cereb Blood Flow Metab，2022，42（11）：2107-2122. [62] BANH R S，IORIO C，MARCOTTE R，et al. PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia[J]. Nat Cell Biol，2016，18（7）：803-813. [63] SIGDEL T K，SHOEMAKER L D，CHEN R，et al. Immune response profiling identifies autoantibodies specific to Moyamoya patients[J/OL]. Orphanet J Rare Dis，2013，8：45[2024-03-22]. http://doi.org/10.1186/1750-1172-8-45. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
